Phase 2 N=112 Safety and Immunogenicity of ChimeriVax-WN02 West Nile Vaccine in Healthy Adults
West Nile Fever
Primary: Number of Participants With Fourfold or Greater Post-vaccination Titers (Seroconversion). — 0; 21; 36; 27 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=479 Safety and Immunogenicity Study of ChimeriVax West Nile Vaccine in Healthy Adults
West Nile Fever
Primary: Geometric Mean Titers (GMTs) of Antibodies to Vaccination With ChimeriVax™ WN02 or a Placebo Vaccine — 5.00; 5.76; 5.06; 5.22 Titers
Phase 1 N=30 VRC 313: A Trivalent Virus-like Particle (VLP) Encephalitis Vaccine (WEVEE) in Healthy Adults
Venezuelan Equine Encephalitis · Western Equine Encephalitis · Eastern Equine Encephalitis
Primary: Number of Subjects Reporting Local Reactogenicity Signs and Symptoms For 7 Days After Each Product Administration — 4; 2; 0; 1 Participants
Phase 2 N=10 Safety Evaluation of a Q-fever Vaccine, NDBR 105
Q Fever
Primary: The Adverse Reaction and Occupational Illness Endpoint Measurements in This Q Fever NDBR 105 Vaccine Study Will be Evaluated for All Intent-to-treat Volunteers. — 10…
N/A N=300 Sylvatic Transmission of Zika, Dengue, and Chikungunya Viruses in Thailand and Cambodia
Dengue Fever · Zika · Vector-Borne Diseases
Primary: Assessment of DENV, ZIKV, CHIKV Seroprevalence Via Screening PRNT50 Titers in Cambodian Adults. — 300 Participants